How large is the cell and gene therapy contract development and manufacturing organization (cdmo) market, and what is its growth trajectory?
The cell and gene therapy contract development and manufacturing organization (CDMO) market size has grown exponentially in recent years. It will grow from $5.41 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.
The cell and gene therapy contract development and manufacturing organization (CDMO) market size is expected to see exponential growth in the next few years. It will grow to $18.54 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.
Get Your Free Sample of The Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
What are the key forces behind the cell and gene therapy contract development and manufacturing organization (cdmo) market’s growth in recent years?
The growing prevalence of cancer cases is expected to propel the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market going forward. Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells in the body. The growing prevalence of cancer cases is due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. Cell and gene therapy contract development and manufacturing organization (CDMO) helps reduce cancer prevalence by developing and manufacturing innovative, targeted treatments that enhance efficacy and patient outcomes. For instance, in October 2022, according to Macmillan Cancer Support, a UK-based charitable organization, the estimated number of people living with cancer in the UK is projected to increase from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer cases drives the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.
What are the major segments of the cell and gene therapy contract development and manufacturing organization (cdmo) market?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
Order your report now for swift delivery
Which companies dominate the cell and gene therapy contract development and manufacturing organization (cdmo) market?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.
What major trends will shape the cell and gene therapy contract development and manufacturing organization (cdmo) market during the forecast period?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focused on expanding their portfolio with advanced solutions such as PluriMatrix technology to enhance the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system tailored for the large-scale production of cell-based products. This advanced technology facilitates the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division that offers cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri’s newly established division offers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company’s cutting-edge PluriMatrix technology to offer advanced cell therapy manufacturing services.
What are the key regional dynamics of the cell and gene therapy contract development and manufacturing organization (cdmo) market, and which region leads in market share?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report 2025 Offer?
The cell and gene therapy contract development and manufacturing organization (cdmo) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients’ needs from early-stage development through commercialization.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
